1. Tamoxifen-associated skin reactions in breast cancer patients: from case report to literature review

   • Peter Andrew
   • Sabira Valiani
   • Shailendra Verma

   Review 08 October 2014 Pages: 1 - 5

   

2. Wild-type p53 inhibits pro-invasive properties of TGF-β3 in breast cancer, in part through regulation of EPHB2, a new TGF-β target gene

   • Suzanne Lam
   • Eliza Wiercinska
   • Aart G. Jochemsen

   Preclinical Study 26 September 2014 Pages: 7 - 18

   

3. Growth and metastatic behavior of molecularly well-characterized human breast cancer cell lines in mice

   • Muhammad Riaz
   • Buddy Setyono-Han
   • John W. M. Martens

   Preclinical study 30 September 2014 Pages: 19 - 31

   

4. Whole breast proton irradiation for maximal reduction of heart dose in breast cancer patients

   • Mirjam E. Mast
   • Eline J. Vredeveld
   • John H. Maduro

   Preclinical study Open access 01 October 2014 Pages: 33 - 39

   

5. Infiltrating S100A8+ myeloid cells promote metastatic spread of human breast cancer and predict poor clinical outcome

   • Katherine Drews-Elger
   • Elizabeth Iorns
   • Marc E. Lippman

   Preclinical Study 01 October 2014 Pages: 41 - 59

   

6. Pigment epithelium-derived factor (PEDF) inhibits breast cancer metastasis by down-regulating fibronectin

   • Honghai Hong
   • Ti Zhou
   • Guoquan Gao

   Preclinical study 05 October 2014 Pages: 61 - 72

   

7. Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series

   • Luigi Di Lauro
   • Patrizia Vici
   • Marcello Maugeri-Saccà

   Clinical trial 20 September 2014 Pages: 73 - 80

   

8. Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial

   • Andrea DeCensi
   • Matteo Puntoni
   • Michael N. Pollak

   Clinical trial Open access 25 September 2014 Pages: 81 - 90

   

9. Treatment factors affecting breast cancer-related lymphedema after systemic chemotherapy and radiotherapy in stage II/III breast cancer patients

   • So-Youn Jung
   • Kyung Hwan Shin
   • Jungsil Ro

   Clinical trial 25 September 2014 Pages: 91 - 98

   

10. A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007

    • Kathy D. Miller
    • Sandra K. Althouse
    • Patricia S. Steeg

    Clinical trial 26 September 2014 Pages: 99 - 106

    

11. A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy

    • Anton Buchner
    • Reiner Elsässer
    • Peter Bias

    Clinical trial Open access 27 September 2014 Pages: 107 - 116

    

12. Can mammographic and sonographic imaging features predict the Oncotype DX™ recurrence score in T1 and T2, hormone receptor positive, HER2 negative and axillary lymph node negative breast cancers?

    • Monica Maria Yepes
    • Ada Pat Romilly
    • Stefan Glück

    Clinical Trial 28 September 2014 Pages: 117 - 123

    

13. Understanding process-of-care delays in surgical treatment of breast cancer at a comprehensive cancer center

    • Mehra Golshan
    • Katya Losk
    • Craig Bunnell

    Clinical trial 01 October 2014 Pages: 125 - 133

    

14. No increased venous thromboembolism risk in Asian breast cancer patients receiving adjuvant tamoxifen

    • Tom Wei-Wu Chen
    • Ho-Min Chen
    • Yen-Shen Lu

    Epidemiology 21 September 2014 Pages: 135 - 142

    

15. Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies

    • Jessica Salmen
    • Julia Neugebauer
    • Brigitte Rack

    Epidemiology 25 September 2014 Pages: 143 - 151

    

16. Diabetes, diabetes treatment and breast cancer prognosis

    • Juhua Luo
    • Beth Virnig
    • Karen Margolis

    Epidemiology 27 September 2014 Pages: 153 - 162

    

17. Racial disparities in risk of second breast tumors after ductal carcinoma in situ

    • Ying Liu
    • Graham A. Colditz
    • Melody Goodman

    Epidemiology 27 September 2014 Pages: 163 - 173

    

18. Erythropoiesis stimulating agents and clinical outcomes of invasive breast cancer patients receiving cytotoxic chemotherapy

    • Yinzhi Lai
    • Juan P. Palazzo
    • Hushan Yang

    Epidemiology 27 September 2014 Pages: 175 - 185

    

19. Mammography interval and breast cancer mortality in women over the age of 75

    • Michael S. Simon
    • Sylvia Wassertheil-Smoller
    • Lew H. Kuller

    Epidemiology 25 September 2014 Pages: 187 - 195

20. Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer

    • Kazuhiro Araki
    • Ippei Fukada
    • Yoshinori Ito

    Epidemiology 01 October 2014 Pages: 197 - 209

    

21. Dual specificity phosphatase 4 gene expression in association with triple-negative breast cancer outcome

    • Michelle L. Baglia
    • Qiuyin Cai
    • Xiao-Ou Shu

    Epidemiology 04 October 2014 Pages: 211 - 220

    

22. Expression of regulators of mitotic fidelity are associated with intercellular heterogeneity and chromosomal instability in primary breast cancer

    • Rebecca Roylance
    • David Endesfelder
    • Charles Swanton

    Brief Report 07 October 2014 Pages: 221 - 229

    

23. Response to the article by Evangelista et al.: Use of a portable gamma camera for guiding surgical treatment in locally advanced breast cancer in a post-neoadjuvant therapy setting. Breast Cancer Res Treat 2014

    • Alexandre Bricou
    • Emmanuel Barranger

    Letter to the Editor 25 July 2014 Pages: 231 - 232